SilkRoad Technology Recognized as a Core Leader in 2020 Fosway 9-Grid™ for Talent Acquisition
28.5.2020 15:00:00 EEST | Business Wire | Press release
SilkRoad Technology, a global software and services platform that helps organisations attract, retain and align people to its business, today announced its recognition as a Core Leader in the 2020 Fosway 9-Grid™ for Talent Acquisition. This position acknowledges SilkRoad Technology for growth and innovation in its talent experience capabilities, as well as for the company's continued customer growth, success and advocacy across the European market.
SilkRoad Technology’s Talent Acquisition services and software help organisations optimise talent by attracting the right calibre of candidate to the business. HR and business decision-makers can streamline recruiting processes from requisition to job offer through SilkRoad’s scalable, personalised and on-brand solution that drives engagement and retention. Once the right talent is identified and secured, SilkRoad’s onboarding solution provides clarity, alignment and enablement to employees which helps accelerate revenue for efficient cost management in the midst of evolving workforce transformation.
“Being viewed as a Core Leader by Fosway is a great achievement for SilkRoad Technology. The Talent acquisition marketplace continues to face significant change and disruption particularly in these extremely difficult times. That’s why we continue to heavily invest finances and staff time in the development of our solution’s, so they are fit not only for today’s business challenges but also agile enough to evolve for the challenges of tomorrow as well,” said Colin Larter, Senior Director, SilkRoad EMEA.
The Fosway Group 9-Grid™ is a five-dimensional market analysis model that helps organisations understand the relative position of solutions and providers in the learning and talent systems market. It is based on Fosway Group’s independent research in the HR, talent and learning market throughout the past 20 years, and draws on insight and experience of its Corporate Research Network. The Corporate Research Network is a group of HR and learning professionals, who among them represent more than 150 of Europe’s leading companies. The 2018 Fosway 9-Grid™ for Talent Acquisition is available here.
“Silkroad is a new addition to the 2020 Fosway 9-Grid™ for Talent Acquisition. Whilst Silkroad plays in multiple parts of the talent lifecycle, its specialist focus on onboarding is central to our assessment and rating as a Core Leader,” said David Wilson, CEO of Fosway Group. “SilkRoad’s recognition reflects its proven capability to provide European companies with much needed expertise in a critical area of success.”
About Fosway
Fosway Group is Europe's #1 HR Industry Analyst. The Fosway 9-Grid provides a unique assessment of the principal learning and talent supply options available to organisations in EMEA. The 9-Grids help European buyers demystify supplier decisions for next gen HR, Talent and Learning. Fosway Group have provided expert independent advice to corporate clients for over 20 years.
Visit the Fosway website at www.fosway.com for more information on Fosway Group's research and services.
About SilkRoad Technology
Since 2003, SilkRoad Technology’s software and services platform helps our clients attract, retain and align people to their business. Our solutions start with Global Client Services to provide strategic HR and business expertise. SilkRoad then designs secure solutions tailored to your business requirements at scale for global companies. We deliver personalised experiences for employees to drive engagement across the employment lifecycle to enable measurable and better business outcomes.
For more information, visit www.silkroadtechnology.com, follow on Twitter @SilkRoadTweets or call 866-329-336. (U.S. toll free) or +1-312-574-3700.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005286/en/
Contact information
Karl Fruecht
847.732.3920
Karl.Fruecht@silkroad.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom